Humacyte Inc (HUMA)vsVertex Pharmaceuticals Inc (VRTX)
HUMA
Humacyte Inc
$0.57
+0.09%
HEALTHCARE · Cap: $165.73M
VRTX
Vertex Pharmaceuticals Inc
$515.44
+0.17%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 593356% more annual revenue ($12.59B vs $2.12M). VRTX leads profitability with a 35.0% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
HUMA
Avoid24
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+59.9%
Fair Value
$2.52
Current Price
$0.57
$1.95 discount
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$515.44
$448.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.9% year-over-year
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -839.6% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : HUMA
The strongest argument for HUMA centers on Revenue Growth. Revenue growth of 34.9% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : HUMA
The primary concerns for HUMA are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 2.12 is elevated, increasing financial risk.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
HUMA profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
HUMA carries more volatility with a beta of 2.47 — expect wider price swings.
HUMA is growing revenue faster at 34.9% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 24/100), backed by strong 35.0% margins and 12.5% revenue growth. HUMA offers better value entry with a 59.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Humacyte Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs). These innovative, off-the-shelf products are designed to meet pressing needs in vascular reconstruction and chronic disease management, improving patient outcomes and potentially reducing healthcare expenses. Leveraging its advanced technology platform, Humacyte is strategically positioned to drive innovation in transplantation and tissue engineering, thereby cementing its status as a transformative leader within the rapidly evolving landscape of medical therapies.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?